HUTCHMED’s Sovleplenib Hits Phase III Goal in Warm Autoimmune Hemolytic Anemia Trial in China

HUTCHMED (China) ( (HK:0013) ) has issued an update.

HUTCHMED announced that the Phase III registration part of its ESLIM-02 trial in China for sovleplenib, an oral spleen tyrosine kinase (Syk) inhibitor, in adults with relapsed or refractory warm antibody autoimmune hemolytic anemia (wAIHA) met its primary endpoint, demonstrating durable hemoglobin responses between weeks 5 and 24. The positive topline data, following earlier Phase II results showing meaningful hemoglobin improvements and a favorable safety profile, underscore sovleplenib’s potential as a new treatment option in wAIHA, a prevalent and often serious form of autoimmune hemolytic anemia with limited therapies after standard treatments fail. HUTCHMED plans to submit a New Drug Application for sovleplenib in wAIHA to China’s National Medical Products Administration in the first half of 2026, while continuing to develop the drug in immune thrombocytopenia, where it has also shown positive Phase III results, reinforcing the company’s positioning in autoimmune hematologic diseases and its strategy to retain global rights to the asset.

The most recent analyst rating on (HK:0013) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.

More about HUTCHMED (China)

HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. The company advances drug candidates from in-house discovery to global markets, with three medicines already marketed in China and one also approved in the US, Europe and Japan.

Average Trading Volume: 4,966,024

Technical Sentiment Signal: Sell

Current Market Cap: HK$18.48B

Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.